Doctor of Medical Science Danish Medical Journal

I. Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2012;36:650-659. II. Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Individualized therapy is more cost-effective than dose intensification in Crohn's disease patients who fail anti-TNF treatment: a randomized, controlled trial. Gut 2014;63:919-927. III. Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, Kjellberg J, Bendtzen K, Ainsworth MA. Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. Dig Dis Sci. 2015;60:2762-2770. IV. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA. Changes in serum through levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn’s disease. J Crohns Colitis 2015;9:238-245. V. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn’s disease: post-hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014;109:1055-1064. VI. Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OØ, Bendtzen K, Steenholdt C. Antibodies against infliximab (IFX) are associated with de novo development of antibodies to adalimumab (ADL) and therapeutic failure in IFX-toADL switchers with inflammatory bowel disease. Inflamm Bowel Dis 2014;20:1714-1721. VII. Steenholdt C, Frederiksen MT, Bendtzen K, Ainsworth MA, Thomsen OØ, Brynskov J. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. J Clin Gastroenterol. 2015 Jul 9. [Epub ahead of print] VIII. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Thomsen OØ, J Seidelin. Outcome after discontinuing infliximab in patients with inflammatory bowel disease in clinical remission: An observational Danish single center study. Scand J Gastroenterol. 2012;47:518-527. IX. Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA. Implications of infliximab treatment failure and influence of personalized treatment on patient-reported health-related quality of life and productivity outcomes in Crohn’s disease. J Crohns Colitis. 2015;9:1032-1042.